Skip to Content

Posts tagged with "Cardiovascular Disease"

  • Cardiovascular Disease

    Mipomersen – It Still Works

    Isis Pharmaceuticals has had a long, tough history developing antisense-based therapeutics. I’ve lost count of the number of promising candidates they’ve had (and promising deals they’ve signed). But the latest one seems to be progressing: mipomersen, designed to block production of the ApoB lipoprotein. That should lower LDL, and… Read More
  • Aging and Lifespan

    Exercise and Vitamins: Now, Wait A Minute. . .

    Now, this is an example of an idea being followed through to its logical conclusion. Here’s where we start: the good effects of exercise are well known, and seem to be beyond argument. Among these are marked improvements in insulin resistance (the hallmark of type II diabetes) and glucose uptake. In fact, exercise, combined with… Read More
  • Cardiovascular Disease

    Farewell to ACAT, and to Lots of Time and Money, Too

    Back when I joined the first drug company I ever worked for, the group in the lab next door was working on an enzyme called ACAT, acyl CoA:cholesterol acyltranferase. It’s the main producer of cholesterol esters in cells, and is especially known to be active in the production of foam cells in atherosclerosis. It had… Read More
  • Biological News

    Niacin, No Longer Red-Faced?

    One of Merck’s less wonderful recent experiences was the rejection of Cordaptive, which was an attempt to make a niacin combination for the cardiovascular market. Niacin would actually be a pretty good drug to improve lipid profiles if people could stand to take the doses needed. But many people experience a burning, itchy skin flush… Read More
  • Cardiovascular Disease

    The Polypill Rides Again

    There are a lot of recommended mediations for people at cardiovascular risk. ACE inhibitors and diuretics for blood pressure, a bit of aspirin for anti-thrombotic activity, most likely a stain for cholesterol levels. There are plenty of people who are taking all of these at once, and millions are taking some subset of them. So… Read More
  • Cardiovascular Disease

    Takeda Gets A Surprise

    DPP-IV is short for “dipeptidylpeptidase IV”, understandably, and we need a good abbreviation for it. It’s an important enzyme target for diabetes therapy, since under normal conditions it breaks down glucagon-like-peptide 1. Longer-circulating GLP-1 would actually do a lot of diabetics good, and people have actually made such proteins as sep… Read More
  • Cardiovascular Disease

    Torcetrapib: What Was the Problem? And Does It Matter?

    Ever since the catastrophic failure of Pfizer’s HDL-raising CETP inhibitor torcetrapib in late 2006, everyone involved has wondered just what the problem was. There was a definitely higher cardiovascular-linked death rate in the drug-treatment group as opposed to placebo – which led to the screeching halt in Phase III, as well it might… Read More
  • Cardiovascular Disease

    Crestor: Would It Save Any Lives?

    Should millions more people be taking Crestor? That’s a real balancing act. You have a decrease in heart attacks, but from a fairly small incidence rate. So at a minimum, you’ll need to balance the costs of those coronary events versus the cost of paying for all that Crestor. And statins are not without side… Read More
  • Cardiovascular Disease

    Crestor: Risks Up, Risks Down

    AstraZeneca took a pretty big risk in running a trial as big as the JUPITER one, but it seems to have paid off for them. As everyone has been reading, it appears that their Crestor (rosuvastatin), lowers the risk of cardiovascular events in patients with elevated C-reactive protein, even those with reasonable cholesterol numbers. (NEJM… Read More
  • Cardiovascular Disease

    Prasugrel Today?

    I wrote back in the summer about the FDA’s delayed decision on Lilly’s potential anticoagulant blockbuster Effient (prasugrel). Well, those three months have zipped right by, and the agency is supposed to rule today. Prediction, for what it’s worth: I think the drug will be approved, but with label restrictions for the group(s) th… Read More